Cyprotex buys CeeTox to expand preclinical services biz
Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business.
Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business.
Chinese regulators plan to 'blacklist' drugmakers involved in bribery along with those that make 'shoddy' pharmaceuticals.